Mofegiline

Mofegiline (MDL-72,974) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) which was under investigation for the treatment of Parkinson's disease and Alzheimer's disease,[3][4][5][6] but was never marketed.[7]

Mofegiline

Clinical data
Other names	MDL-72,974A
Routes of administration	Oral[1]
ATC code	None
Legal status
Legal status	Development terminated
Pharmacokinetic data
Elimination half-life	1–3 hours[1]
Excretion	Urine[2]
Identifiers
IUPAC name (2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine
CAS Number	119386-96-8
PubChem CID	6437850
ChemSpider	4942371
UNII	1FMJ6D8Y1B
Chemical and physical data
Formula	C11H13F2N
Molar mass	197.229 g·mol^−1
3D model (JSmol)	Interactive image
SMILES Fc1ccc(cc1)CCC(=[C@H]F)CN
InChI InChI=1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2/b10-7+ Key:VXLBSYHAEKDUSU-JXMROGBWSA-N

See also

• Ladostigil
• Lazabemide
• Rasagiline
• Selegiline

References

1. Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S (September 1995). "Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial". Clinical Pharmacology and Therapeutics. 58 (3): 342–53. doi:10.1016/0009-9236(95)90252-X. PMID 7554709.
2. Dulery BD, Schoun J, Zreika M, et al. (March 1993). "Pharmacokinetics of and monoamine oxidase B inhibition by (E)-4-fluoro-beta-fluoromethylene benzene butanamine in man". Arzneimittel-Forschung. 43 (3): 297–302. PMID 8489556.
3. Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A (1988). "Design and early clinical evaluation of selective inhibitors of monoamine oxidase". Progress in Neuro-psychopharmacology & Biological Psychiatry. 12 (6): 967–87. doi:10.1016/0278-5846(88)90092-9. PMID 3266532.
4. Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG (1989). "MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease". Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 1 (4): 243–54. doi:10.1007/bf02263478. PMID 2597310.
5. Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Cremer G (1994). "Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential". Journal of Neural Transmission. Supplementum. 41: 407–14. doi:10.1007/978-3-7091-9324-2_54. ISBN 978-3-211-82521-1. PMID 7931257.
6. Thiffault C, Quirion R, Poirier J (March 1998). "Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain". Synapse. 28 (3): 208–11. doi:10.1002/(SICI)1098-2396(199803)28:3<208::AID-SYN3>3.0.CO;2-E. PMID 9488505.
7. Ganellin, C. R.; Triggle, D. J.; Macdonald, F. (1997). Dictionary of pharmacological agents. CRC Press. p. 1370. ISBN 978-0-412-46630-4. Retrieved 25 November 2011.